Linked Life Data

7593351

Source:http://linkedlifedata.com/resource/pubmed/id/7593351

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7593351rdf:typepubmed:Citationlld:pubmed
pubmed-article:7593351lifeskim:mentionsumls-concept:C0028128lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C0521119lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C0032821lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C0212320lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C1428360lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:7593351lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:7593351pubmed:issue6lld:pubmed
pubmed-article:7593351pubmed:dateCreated1995-12-13lld:pubmed
pubmed-article:7593351pubmed:abstractTextThe response of the regional cerebral blood flow (rCBF) to brain topical superfusion of 20 mM K+ was characterized in a closed cranial window preparation in barbiturate anesthetized and ventilated rats: Increasing K+ in the artificial cerebrospinal fluid (ACSF) induced a rCBF elevation (measured by laser-Doppler flowmetry) of +85 +/- 37% above baseline (n = 19). This elevation was stable for > 3 h with continuous superfusion of increased K+ (n = 5) and partially reversible to a level of +18 +/- 19% above baseline when returning to a physiological K+ concentration. Nitric oxide synthase (NOS) inhibition by brain topical superfusion with N omega-nitro-L-arginine (L-NA) revealed (a) Addition of L-NA to high-potassium ACSF reduced the rCBF increase from +94 +/- 36% to +21 +/- 18% (p < or = 0.01, n = 7). (b) When L-NA was superfused for 60 min before increasing K+, rCBF decreased to -17 +/- 7% below baseline. Subsequent coapplication of L-NA and increased K+ induced only an elevation of +7 +/- 4% above baseline (n = 4). (c) When the NO donor S-nitroso-N-acetylpenicillamine (SNAP) was added during NOS inhibition to restore basal tissue NO levels, the resultant level of rCBF was +28 +/- 54% above baseline. Subsequent increase of K+ in the presence of NOS inhibition and SNAP elevated rCBF to +137 +/- 89% above baseline (n = 4).(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7593351pubmed:languageenglld:pubmed
pubmed-article:7593351pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7593351pubmed:citationSubsetIMlld:pubmed
pubmed-article:7593351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7593351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7593351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7593351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7593351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7593351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7593351pubmed:statusMEDLINElld:pubmed
pubmed-article:7593351pubmed:monthNovlld:pubmed
pubmed-article:7593351pubmed:issn0271-678Xlld:pubmed
pubmed-article:7593351pubmed:authorpubmed-author:KörnerKKlld:pubmed
pubmed-article:7593351pubmed:authorpubmed-author:WeirWWlld:pubmed
pubmed-article:7593351pubmed:authorpubmed-author:DreierJ PJPlld:pubmed
pubmed-article:7593351pubmed:authorpubmed-author:VillringerAAlld:pubmed
pubmed-article:7593351pubmed:authorpubmed-author:DirnaglUUlld:pubmed
pubmed-article:7593351pubmed:authorpubmed-author:GörnerAAlld:pubmed
pubmed-article:7593351pubmed:authorpubmed-author:LindauerUUlld:pubmed
pubmed-article:7593351pubmed:issnTypePrintlld:pubmed
pubmed-article:7593351pubmed:volume15lld:pubmed
pubmed-article:7593351pubmed:ownerNLMlld:pubmed
pubmed-article:7593351pubmed:authorsCompleteYlld:pubmed
pubmed-article:7593351pubmed:pagination914-9lld:pubmed
pubmed-article:7593351pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:meshHeadingpubmed-meshheading:7593351-...lld:pubmed
pubmed-article:7593351pubmed:year1995lld:pubmed
pubmed-article:7593351pubmed:articleTitleNitric oxide modulates the CBF response to increased extracellular potassium.lld:pubmed
pubmed-article:7593351pubmed:affiliationDepartment of Neurology, Charité Humboldt University, Berlin, Germany.lld:pubmed
pubmed-article:7593351pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7593351pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7593351lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7593351lld:pubmed